Left ventricular assist device support normalizes left and right ventricular beta-adrenergic pathway properties

Area of Science:

• Cardiology
• Biomedical Engineering
• Heart Failure Research

Background:

• The mechanisms driving reverse remodeling in hearts supported by left ventricular assist devices (LVADs) are not fully understood.
• The relative contributions of hemodynamic unloading versus neurohormonal normalization to reverse remodeling remain unclear.

Purpose of the Study:

• To investigate whether reverse remodeling induced by LVADs is primarily driven by neurohormonal normalization rather than hemodynamic factors.
• To elucidate the role of the neurohormonal milieu in LVAD-mediated cardiac reverse remodeling.

Main Methods:

• Comparison of structural and functional heart characteristics in medically managed patients, LVAD patients, and donor hearts.
• Assessment of ventricular volume (V(30)), beta-adrenergic stimulation response, receptor density, and protein kinase A (PKA) phosphorylation of the ryanodine receptor 2 (RyR2).

Main Results:

• LVAD support led to lower diastolic pulmonary pressures and higher cardiac output.
• Significant improvements in contractility and beta-adrenergic responsiveness were observed in both left and right ventricles of LVAD patients.
• LVAD support increased beta-adrenergic receptor density and reduced PKA hyperphosphorylation of RyR2 in both ventricles.

Conclusions:

• LVAD support significantly improves beta-adrenergic responsiveness and normalizes RyR2 PKA phosphorylation.
• Increased beta-adrenergic receptor density in both ventricles suggests a crucial role for the neurohormonal environment in LVAD-mediated reverse remodeling.
• These findings highlight the neurohormonal pathway's importance in cardiac recovery with LVAD support.